You are here: Industry Insights > CGT

News List

Ori Biotech Expands Cell and Gene Therapy Manufacturing Capabilities contractpharma
January 24, 2022
Raises over $100 million in Series B funding to launch innovative cell and gene therapy manufacturing platform.
BioLife Solutions Acquires Sexton Biotechnologies contractpharma
August 10, 2021
Sexton supports cell and gene therapy manufacturing with two product lines; processing and handling solutions, and cell performance supplements.
Ori Biotech and Vineti Enter Non-Exclusive Partnership contractpharma
May 27, 2021
Ori Biotech, an innovator in cell and gene therapy manufacturing, and Vineti, a provider of digital enterprise platforms for cell and gene therapy supply chains, are partnering to produce a fully pre-integrated solution to modernize, fast-track, and ...
Univercells Technologies Collaborates with NIBRT contractpharma
May 20, 2021
Univercells Technologies, a global provider of next-generation biomanufacturing technologies, and the National Institute of Bioprocessing Research and Training (NIBRT) in Dublin, Ireland, are collaborating to address the need for training in cell and ...
Cell and gene therapy: the impact of skills gaps in a fast-growing sector pharmaceutical-technology
April 15, 2021
Cell and gene therapy (CGT) is an experimental space that has grown exponentially in recent years; the sector received nearly $20bn in funding last year, a 50% increase on the record $13.5bn it saw in 2018.
ATMPS, Ori Biotech Integrate Digital Platform for Cell & Gene Therapies contractpharma
April 15, 2021
Aims to provide improved product tracking, scheduling and live monitoring of the manufacturing status across the entire CGT supply chain from vein to vein.
Glenmark Pharma gets ANDA approval for chlorpromazine hydrochloride tablets expresspharma
March 25, 2021
Granted competitive generic therapy designation and is eligible for 180 days of CGT exclusivity.
GSK to leverage the Cell and Gene Therapy Catapult’s facility in Stevenage pharmatimes
March 12, 2021
GlaxoSmithKline (GSK) is set to leverage the Cell and Gene Therapy (CGT) Catapult’s facility in Stevenage to expand its own clinical trial manufacturing capacity for cell and gene therapy.
Lonza and Be The Match BioTherapies Enter CGT Partnership contractpharma
November 25, 2020
Be The Match BioTherapies, an organization offering solutions for companies developing and commercializing cell and gene therapies (CGT), and Lonza have entered a partnership to integrate industry-leading solutions in CGT.
Cipla receives final approval for generic version of Migranal with a Competitive Generic Therapy Des expresspharma
May 21, 2020
Cipla is the “first approved applicant” for such CGT and, is therefore, eligible for 180 days of CGT exclusivity which will begin to run from the commercial marketing of Cipla’s product.

Previous page 1 2 Next page